26 years of historical data (1999–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rigel Pharmaceuticals, Inc. trades at 35.1x earnings, 107% above its 5-year average of 17.0x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 48%. On a free-cash-flow basis, the stock trades at 19.8x P/FCF, 59% below the 5-year average of 47.8x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $615M | $297M | $252M | $259M | $452M | $591M | $358M | $369M | $490M | $225M | $268M |
| Enterprise Value | $618M | $301M | $280M | $276M | $463M | $599M | $372M | $293M | $452M | $210M | $231M |
| P/E Ratio → | 35.09 | 16.99 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.43 | 1.66 | 2.16 | 2.15 | 3.03 | 5.44 | 6.04 | 8.30 | 109.30 | 11.02 | 9.27 |
| P/B Ratio | 186.88 | 90.48 | — | — | 14.87 | 17.36 | 6.66 | 3.36 | 4.87 | 4.08 | 2.93 |
| P/FCF | 19.80 | 9.57 | — | — | 86.04 | — | — | — | — | — | — |
| P/OCF | 19.55 | 9.45 | — | — | 76.86 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Rigel Pharmaceuticals, Inc.'s enterprise value stands at 23.4x EBITDA, 106% above its 5-year average of 11.4x. The Healthcare sector median is 13.8x, placing the stock at a 69% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.68 | 2.40 | 2.29 | 3.11 | 5.52 | 6.27 | 6.58 | 100.83 | 10.33 | 7.99 |
| EV / EBITDA | 23.41 | 11.38 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 25.57 | 11.44 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 9.68 | — | — | 88.26 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Rigel Pharmaceuticals, Inc. earns an operating margin of 13.5%. Operating margins have expanded from -46.2% to 13.5% over the past 3 years, signaling improving operational efficiency. Return on equity of 531.8% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks. ROIC of 641.6% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.6% | 89.6% | 93.9% | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% | -931.9% | -211.3% | -117.4% |
| Operating Margin | 13.5% | 13.5% | -17.5% | -46.2% | -8.4% | -26.7% | -116.5% | -163.3% | -1775.6% | -342.2% | -179.1% |
| Net Profit Margin | 9.8% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.2% | -158.3% | -1739.3% | -339.6% | -178.1% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 531.8% | 531.8% | — | -699.0% | -55.6% | -67.7% | -81.3% | -67.0% | -100.2% | -94.6% | -46.9% |
| ROA | 12.4% | 12.4% | -20.0% | -38.8% | -12.9% | -23.1% | -46.4% | -54.6% | -79.1% | -66.0% | -36.0% |
| ROIC | 641.6% | 641.6% | -1170.0% | -183.0% | -22.1% | -39.4% | -102.4% | -113.3% | -115.4% | -109.8% | -43.9% |
| ROCE | 29.4% | 29.4% | -30.8% | -64.3% | -14.4% | -36.5% | -68.8% | -68.5% | -101.9% | -90.9% | -43.5% |
Solvency and debt-coverage ratios — lower is generally safer
Rigel Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 2.3x, which is manageable (27% below the sector average of 3.1x). Net debt stands at $3M ($60M total debt minus $57M cash). Interest coverage of 3.1x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 18.24 | 18.24 | — | — | 1.01 | 1.15 | 0.67 | — | 0.00 | 0.06 | 0.07 |
| Debt / EBITDA | 2.27 | 2.27 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.98 | — | — | 0.38 | 0.26 | 0.26 | -0.69 | -0.38 | -0.26 | -0.40 |
| Net Debt / EBITDA | 0.12 | 0.12 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 0.10 | — | — | 2.22 | — | — | — | — | — | — |
| Interest Coverage | 3.06 | 3.06 | -2.98 | -14.99 | -2.57 | -21.41 | -206.24 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
Rigel Pharmaceuticals, Inc.'s current ratio of 2.13x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.78x to 2.13x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.13 | 2.13 | 1.86 | 1.78 | 2.43 | 2.18 | 2.04 | 4.94 | 6.40 | 3.37 | 3.82 |
| Quick Ratio | 2.04 | 2.04 | 1.76 | 1.64 | 2.33 | 2.14 | 2.02 | 4.91 | 6.40 | 3.37 | 3.82 |
| Cash Ratio | 1.22 | 1.22 | 1.07 | 0.89 | 1.97 | 1.40 | 1.68 | 4.63 | 6.31 | 3.31 | 3.74 |
| Asset Turnover | — | 1.09 | 1.00 | 0.90 | 0.89 | 0.98 | 0.40 | 0.32 | 0.04 | 0.26 | 0.22 |
| Inventory Turnover | 3.11 | 3.11 | 1.29 | 0.19 | 0.16 | 0.55 | 0.67 | 0.32 | — | — | — |
| Days Sales Outstanding | — | 84.73 | 95.40 | 122.39 | 37.84 | 53.67 | 62.25 | 33.43 | — | — | 2.56 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rigel Pharmaceuticals, Inc. returns 1.6% to shareholders annually primarily through share buybacks. The earnings yield of 2.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.8% | 5.9% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 5.1% | 10.4% | — | — | 1.2% | — | — | — | — | — | — |
| Buyback Yield | 1.6% | 3.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.6% | 3.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $18M | $17M | $17M | $17M | $17M | $17M | $16M | $13M | $9M | $9M |
Compare RIGL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| RIGLYou | $615M | 35.1 | 23.4 | 19.8 | 89.6% | 13.5% | 531.8% | 641.6% | 2.3 |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| CANF | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| ABVX | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| RAPT | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| TGTX | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| APGE | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RIGL stacks up against sector leader argenx SE.
Start ComparisonRigel Pharmaceuticals, Inc.'s current P/E ratio is 35.1x. The historical average is 60.8x. This places it at the 50th percentile of its historical range.
Rigel Pharmaceuticals, Inc.'s current EV/EBITDA is 23.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.4x.
Rigel Pharmaceuticals, Inc.'s return on equity (ROE) is 531.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -74.2%.
Based on historical data, Rigel Pharmaceuticals, Inc. is trading at a P/E of 35.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Rigel Pharmaceuticals, Inc. has 89.6% gross margin and 13.5% operating margin. Operating margin between 10-20% is typical for established companies.
Rigel Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.